drugset / Trial / NCT04632381
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
RandomizedSequentialQuadruple-blindTreatment
Summary
To evaluate the safety and tolerability, the antiviral activity, and plasma pharmacokinetics (PK) of zotatifin administered intravenously (IV) to adults with mild or moderate COVID-19.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2023-01-12
- Completion
- 2023-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Zotatifin | Small molecule | 0.01 mg/kg | Intravenous |
| Comparator | Zotatifin | Small molecule | 0.02 mg/kg | Intravenous |
| Comparator | Zotatifin | Small molecule | 0.035 mg/kg | Intravenous |